Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Janux Therapeutics logo — Developing unique immunotherapies that generate tumor-specif...

Janux Therapeutics

Developing unique immunotherapies that generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue

Founded 2017 United States San Diego, United States 120 employees IPO Total: $825.30M Biotechnology, Health Care +2

General Information

Company Name Janux Therapeutics
Founded Year 2017
Location United States San Diego, United States
Employees 120
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage IPO
Social

BounceWatch is an independent company data service, not affiliated with Janux Therapeutics. To contact Janux Therapeutics, visit januxrx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Janux Therapeutics compare?

A PDF of Janux Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Janux Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Janux Therapeutics

Janux Therapeutics is an innovative biopharmaceutical company founded in 2017 and based in the United States. The company is focused on developing next-generation therapeutics through its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology with the aim of providing more effective treatment for cancer patients. Its primary focus lies in the development of a novel class of T cell engagers (TCEs) targeting clinically validated drug targets such as prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). While TCE therapeutics have shown promise in hematological cancers, existing technologies have faced challenges including immune system overactivation, on-target healthy tissue toxicities, and poor pharmacokinetics. Janux Therapeutics aims to address these limitations using its TRACTr platform technology to engineer product candidates. The company's last investment of $296.50M in post-IPO equity investment was made on 29 February 2024. Currently, all of its programs are in the IND-enabling or discovery stage. With its innovative approach and strong financial backing, Janux Therapeutics is well-positioned to make significant strides in the biotechnology and pharmaceutical industries.

Business keywords: biopharmaceutical, cancer therapy, T cell engagers, oncology, immune system modulation, solid tumors, drug development, oncology research, immune-mediated therapies

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $300.00M -
01 Dec 2024
Post-IPO Equity $175.00M -
01 Feb 2024
Post-IPO Equity $60.00M -
01 Jul 2023
Series B $222.90M -
01 Jun 2021
Series A $56.00M 5
Avalon Ventures Correlation Ventures RA Capital Management
Avalon Ventures, Correlation Ventures +3
01 Mar 2021
Early VC $11.40M -
01 Jul 2020

Janux Therapeutics Alternatives & Competitors

View All Alternatives
Janux Therapeutics vs
3T Biosciences
3T Biosciences United States

3T is an immunotherapy company developing next-generation, transformative therapies for broad patien...

Series A
26 employees
Biopharma, Biotechnology
Compare Janux Therapeutics vs 3T Biosciences
Janux Therapeutics vs
Simcha Therapeutics
Simcha Therapeutics United States

Overcoming biological challenges in clinically translatable pathways.

Series B
15 employees
Biotechnology, Health and Wellness
Compare Janux Therapeutics vs Simcha Therapeutics
Janux Therapeutics vs
Gracell Biotechnologies
Gracell Biotechnologies China

A Member of the AstraZeneca Group

Acquired
33 employees
Biotechnology, Health Care
Also compare with: Janux Therapeutics vs Harpoon Therapeutics Harpoon Therapeutics Janux Therapeutics vs ImmunoGenesis, Inc. ImmunoGenesis, Inc. View all alternatives

FAQ About Janux Therapeutics

Developing unique immunotherapies that generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue
Janux Therapeutics was founded in 2017.
Janux Therapeutics is headquartered in San Diego, United States.
Janux Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceutical, cancer therapy, T cell engagers and oncology.
Janux Therapeutics has approximately 120 employees.
Janux Therapeutics has completed 6 funding rounds, raising a total of $825.30M. The latest funding stage is IPO.
Top alternatives and competitors to Janux Therapeutics include 3T Biosciences, Simcha Therapeutics, Gracell Biotechnologies, Harpoon Therapeutics, TScan Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Janux Therapeutics and 3T Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Janux Therapeutics, https://bouncewatch.com/company/janux-therapeutics, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout